ISPO

Published in Cancer Detection and Prevention 1997; 21(1):44-50.

Inhibition of Metastasis by Cicaprost in Rats with Established Smt2a Mammary Carcinoma Growth

Michael Schirner MD, Martin R Schneider PhD

Experimental Oncology, Research Laboratories, Schering AG, Berlin, Germany

Address all correspondence and reprint requests to: Michael Schirner MD, Experimental Oncology, Schering AG, Berlin, 13342 Berlin, Germany.

ABSTRACT: Cicaprost, a stable prostacyclin analog has been shown to be antimetastatically active in a series of metastasizing rodent tumors. Whereas starting treatment with Cicaprost on the day of tumor implantation was a characteristic feature of our previous investigations, the present study focused on the antimetastatic potency of Cicaprost in animals with established tumor growth. We have previously reported that, in Wistar-Furth rats bearing subcutaneously implanted SMT2A mammary carcinoma, Cicaprost in daily oral doses of 0.1 to 1.0 mg/kg given from the day of tumor implantation to the end of the experiment led to a strong decrease in the number of lung metastases. The 1.0 mg/kg doses reduced the number of lung metastases by about 95% compared with the control. In the present study, we have examined the effect of delaying the start of treatment in animals with established tumor growth. Cicaprost in daily oral doses of 0.1 mg/kg given from Day 10 until Day 32 reduced the number of lung metastases by about 80% compared with the control. In contrast, surgical removal of palpable primary tumors had no effect on lung metastasis. We conclude that Cicaprost exhibits strong antimetastatic activity in the SMT2A rat mammary carcinoma model and interferes not only with mechanisms of tumor cell- blood cell interaction, tumor cell adhesion, and extravasation, but also with steps following extravasation.

KEY WORDS: cicaprost, tumor metastasis, SMT2A mammary carcinoma, adjuvant treatment, tumor surgery.

http://www.cancerprev.org/Journal/Issues/21/1/168